In HBV liver transplant recipients with current or anticipated exposure to immunomodulators (e.g., checkpoint inhibitors for HCC or biologics for IBD), how do you adjust candidacy for finite prophylaxis and what virologic and immunologic endpoints do you require in routine follow-up before considering withdrawal?